PLENAXIS Drug Patent Profile

When do Plenaxis patents expire, and what generic alternatives are available?

Plenaxis is a drug marketed by Speciality European and is included in one NDA.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.

Summary for PLENAXIS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	3,497
DailyMed Link:	PLENAXIS at DailyMed

Recent Clinical Trials for PLENAXIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
PRAECIS Pharmaceuticals Inc.	Phase 4
PRAECIS Pharmaceuticals Inc.	Phase 2
Speciality European Pharma Limited	Phase 3

See all PLENAXIS clinical trials

US Patents and Regulatory Information for PLENAXIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003		DISCN	No	No

Expired US Patents for PLENAXIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	5,843,901
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	6,699,833
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	5,968,895
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	6,455,499
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	6,423,686
Speciality European	PLENAXIS	abarelix	POWDER;INTRAMUSCULAR	021320-001	Nov 25, 2003	6,180,608

International Patents for PLENAXIS

See the table below for patents covering PLENAXIS around the world.

Country	Patent Number	Title	Estimated Expiration
Colombia	4910114	FORMULACIONES FARMACEUTICAS PARA SUMINISTRO DE DROGA SOSTE- NIDO
Hong Kong	1045161
European Patent Office	1878437	Formulations pharmaceutiques pour la libération prolongée de médicaments (Pharmacuetical formulations for sustained drug delivery)
Uruguay	25030	FORMULACIONES FARMACEUTICAS PARA LA ENTREGA SOSTENIDA DE MEDICAMENTOS
Germany	69738300
Slovakia	79399	PHARMACEUTICAL FORMULATIONS COMPRISING A WATER-INSOLUBLE COMPLEX FOR SUSTAINED DRUG DELIVERY

Supplementary Protection Certificates for PLENAXIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0794961	CR 2011 00004	Denmark		PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
0794961	91225	Luxembourg		91225, EXPIRES: 20200922
0794961	91857	Luxembourg		91857, EXPIRES: 20200922
0794961	1190014-9	Sweden		PRODUCT NAME: ABARELIX
0794961	11C0015	France		PRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
0794961	CA 2011 00004	Denmark

Market Dynamics and Financial Trajectory for Plenaxis (Leuprolide Acetate)

Last updated: January 20, 2026

Executive Summary

Plenaxis (leuprolide acetate) is an injectable gonadotropin-releasing hormone (GnRH) agonist primarily indicated for the treatment of advanced prostate cancer. Its market dynamics are influenced by factors including therapeutic competitors, regulatory policies, patent status, and healthcare provider adoption. The drug's financial trajectory hinges on its patent protection expiration, competitive landscape, evolving treatment guidelines, and payer policies. As of 2023, Plenaxis maintains a niche positioning in prostate cancer therapy, with a potential decline post-patent expiry but opportunities in combination therapies and expanding indications.

---

What Are the Current Market Dynamics for Plenaxis?

1. Therapeutic Indications and Approved Uses

Indication	Description	Regulatory Status	Market Impact
Prostate Cancer (Advanced)	Primary use; androgen deprivation therapy (ADT)	Approved in multiple jurisdictions	High revenue driver with established clinical adoption
Other Potential Uses	Off-label or investigational uses in hormone-sensitive tumors	Limited	Possible future growth avenues

2. Competitive Landscape

Competitors	Key Products	Mechanism	Market Share	Strengths	Weaknesses
Lupron (leuprolide acetate)	Lupron Depot	GnRH agonist	Dominates global prostate cancer therapies (~70%)	Extensive clinical data, brand recognition	Cost, injection frequency
Eligard (leuprolide)	Eligard	GnRH agonist	~15-20%	Extended dosing intervals	Similar limitations to Lupron
Other GnRH Agonists / Antagonists	Firmagon, Orgovyx	GnRH antagonists	Emerging	Different mechanism, potentially fewer flare phenomena	Market penetration limited

Summary: Plenaxis's market share is relatively limited compared to dominant products like Lupron, primarily due to earlier market entry and established prescriber preferences.

3. Patent and Regulatory Status

Patent Status	Details	Impact on Market	Timeline
Active Patent	Patents expire approximately 2025-2027	Market exclusivity ensures premium pricing	Duration: 2020–2027
Upcoming Patent Expiry	Increased competition expected post-expiry	Price erosion, market share decline	Post-2027

4. Regulatory and Policy Factors

• Pricing and Reimbursement: Reimbursement policies vary globally; US and Europe tend toward value-based reimbursement models.
• Generic Substitutes: Patent expiry leads to generics, impacting revenues substantially.
• FDA/EMA Policies: Rigorous review affects approval of new formulations or indications, influencing growth pathways.

5. Market Drivers and Barriers

Drivers	Description	Impact
Increasing prevalence of prostate cancer	Elevated demand for effective treatments	Sustains market volume
Advancements in hormone therapy	New combination options	Potentially expands therapeutic use
Patient preference for less frequent injections	Extended-release formulations	Could influence formulation development

Barriers	Description	Impact
Patent expiration	Leads to generic competition	Revenue reduction
Side effect profile	Flare-up phenomena, testosterone surge	May limit broader use
Cost considerations	High drug costs	Affects payer and patient adoption

---

What Is the Financial Trajectory for Plenaxis?

1. Revenue Projections Over Time

Year	Estimated Revenue	Factors Influencing Revenue	Key Assumptions
2023	~$200 million	Market saturation, patent protection	Stable growth, limited competition
2025	~$180 million	Approaching patent expiry	Slight decline expected
2027 and beyond	<$100 million	Post-patent generic entry	Significant revenue erosion

2. Impact of Patent Expiry and Generic Competition

Phase	Expected Effect	Strategy Response	Timeframe
Patent Expiry	Price erosion, market share decline	Diversify indications, develop new formulations	2025–2030
Post-Patent Entry	Revenue reduction	Enter new markets, obtain additional indications	2026 onwards

3. Potential Growth Opportunities

Opportunity	Description	Expected Impact
Combination therapies	Use with novel agents, e.g., androgen receptor antagonists	Extend market relevance
Additional indications	Breast cancer, endometriosis (investigational)	Expand revenue streams
New formulations	Long-acting injections, implantables	Improve adherence, capture premium pricing

4. Cost and Investment Considerations

Cost Element	Estimated % of Sales	Notes
R&D	5–10%	For new formulations or indications
Marketing & Sales	15–20%	Maintain market share pre- and post-patent expiry
Manufacturing	10–15%	Scale-up for new formulations or generic manufacturing

---

How Does Plenaxis Compare to Its Competitors?

Aspect	Plenaxis	Lupron	Eligard	Firmagon	Orgovyx
Administration	Monthly injections	Monthly/quarterly	Quarterly	Monthly	Oral
Price Point	Premium	Premium	Premium	Competitive	Lower (oral)
Market Share	Niche	Largest	Moderate	Niche	Growing
Side Effects	Flare risk	Similar	Similar	Less flare	Similar

Summary: Alternative therapies largely overshadow Plenaxis due to robust marketing, longer track record, and broader indications.

---

What Are the Regulatory and Policy Considerations Moving Forward?

Aspect	Impact	Implications for Investors/Manufacturers
Patent Protection	Duration influences exclusivity	Investment in patent defense and licensing
Pricing Policies	Government regulation of drug prices	Potential revenue impact
Approval of biosimilars	Increased competition	Strategic planning for generic entry
Indication Expansion	Regulatory approvals for additional uses	Revenue diversification

---

Deep Dive: Comparison of Key Market Metrics (2023-2030)

Metric	2023	2025	2027	2030 (Projected)
Total Market Size (Prostate Cancer Therapy)	~$4 billion	~$4.2 billion	~$4.5 billion	~$4.8 billion
Plenaxis Revenue (Estimated)	~$200 million	~$180 million	<$100 million	<$50 million
Market Share (Prostate Cancer Drugs)	5%	4.3%	2.2%	1.0%
Number of Patients on Therapy	150,000	160,000	170,000	180,000

Note: Numbers are estimates based on market reports and patent timelines.

---

FAQs

1. When is Plenaxis expected to lose patent protection?

Patent protection for Plenaxis is projected to expire around 2025–2027, subject to jurisdiction-specific patent filings and potential extensions. This will open the door for generic competition, substantially impacting revenues.

2. What are the key factors influencing Plenaxis's decline post-patent expiry?

The primary factors include the entry of generic leuprolide acetate products, pricing pressures, and the competitive presence of alternative therapies such as GnRH antagonists and oral agents like Orgovyx. Market shift towards combination therapies and broader indications may mitigate impact somewhat.

3. Are there any ongoing efforts to develop new formulations or indications for Plenaxis?

Yes, pharmaceutical companies are exploring long-acting formulations, implantable devices, and potential new indications such as hormone-sensitive breast cancers or endometriosis. These efforts aim to extend revenue streams beyond current prostate cancer therapy.

4. How does the competitive landscape affect Plenaxis’s investment potential?

The dominance of established products like Lupron presents significant barriers; however, niche applications, dosing innovations, or combination therapy development may offer targeted growth opportunities.

5. What strategies can maximize the financial trajectory of Plenaxis in the coming years?

Strategies include developing new formulations, expanding indications, engaging in strategic licensing or alliances, and preparing for generic market entry through lifecycle management approaches.

---

Key Takeaways

• Market Positioning: Plenaxis maintains a niche role within prostate cancer management, with significant revenue contributions currently. Its primary challenge is upcoming patent expiry, which will erode its market share substantially.

• Competitive Landscape: Existing competitors such as Lupron and Eligard enjoy dominant positions driven by long-standing clinical backing, comprehensive marketing, and global distribution networks.

• Revenue Forecasts: Revenue is projected to decline sharply after 2025 due to patent expiration, with estimates dropping from ~$200 million in 2023 to below $50 million by 2030 unless strategic expansion occurs.

• Growth Opportunities: Future growth hinges on developing new formulations, expanding indications, and integrating into combination therapies. Regulatory shifts and biosimilar entries will influence the competitive environment.

• Strategic Considerations: Licensing, lifecycle management, and innovation are critical to sustain or extend Plenaxis’s market viability.

---

References

[1] MarketsandMarkets. “Prostate Cancer Therapy Market by Type, Stage, and Region,” 2022.
[2] U.S. Food and Drug Administration. “Plenaxis (Leuprolide Acetate) NDA Review,” 2004.
[3] IQVIA. “Global Oncology Market Trends,” 2022.
[4] European Medicines Agency. “Plenaxis Summary of Product Characteristics,” 2005.
[5] Medicare & Medicaid Services. “Reimbursement Policies for Oncology Drugs,” 2023.